Dementia/Alzheimers Biomarker Panel (Plasma pTau217/ ß-Amylo (Plasma pTau217/ ß-Amyloid 1-42 Ratio)

Plasma pTau217 measures a phosphorylated form of the tau protein found in the blood. Elevated levels are strongly associated with Alzheimer's disease and can indicate abnormal tau accumulation occurring within the brain during the disease process.

The β-Amyloid 1-42 ratio evaluates the balance of amyloid proteins circulating in the blood. An abnormal ratio may reflect amyloid plaque formation in the brain, one of the characteristic biological features of Alzheimer's disease.

Studies have shown that plasma pTau217 and β-Amyloid biomarkers demonstrate high accuracy in identifying Alzheimer's-related pathology. However, no laboratory test is perfect, and results should always be evaluated by an experienced healthcare professional.

This blood test complements, but does not completely replace, imaging studies such as MRI or PET scans. Depending on your symptoms and clinical findings, your doctor may recommend imaging to obtain additional diagnostic information.

Yes. These biomarkers may become abnormal during the early stages of Alzheimer's disease, sometimes before significant memory impairment develops. Early identification can help guide further evaluation, treatment planning, and long-term care strategies.